SAVE THE DATE Alliance for Cancer Gene Therapy 2020 Cancer Summit to be Held in New York City

Feb 03, 2020

Thought leaders in cancer cell and gene therapy research will share the latest advances, address the greatest challenges and showcase the most innovative programs in progress today.

Stamford, CT — Alliance for Cancer Gene Therapy (ACGT) will host its inaugural ACGT 2020 Cancer Summit on April 16, 2020 at the Alexandria Center for Life Science in New York City. The ACGT 2020 Cancer Summit — which launches ACGT’s 20th anniversary — will bring together researchers, companies, investors and advocates in cancer cell and gene therapy to discuss the latest advances, with a focus on combating solid tumors. A partial list of ACGT 2020 Cancer Summit speakers includes:

  • Dara Richardson-Heron, MD – Chief Patient Officer, Pfizer
  • David Weinreich – Senior Vice President, Global Clinical Development, Regeneron
  • Maria Fardis, PhD, MBA – President and CEO, Iovance
  • Gavin Thurston – Vice President, Oncology & Angiogenesis, Regeneron
  • Mitchell H. Finer, PhD – Chief Scientific Officer, ElevateBio, Executive Partner MPM Capital
  • Peter Dudek, PhD – Partner, MRL Ventures Fund
  • Bruce Levine, PhD – Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania
  • Noriyuki Kasahara, MD, PhD – Professor, Neurological Surgery, UCSF
  • Tom Whitehead – Co-Founder, Emily Whitehead Foundation
  • Marc Hurlbert, PhD – Chief Scientific Officer, Melanoma Research Alliance
  • Kerri Kaplan – President & CEO, Lustgarten Foundation
  • Robert Levis – Director, CLL Society

Presenting sponsors include Alexandria Real Estate Equities, Inc./Alexandria Venture Investment. Additionally, STAT will be a media partner for the ACGT 2020 Cancer Summit. For more sponsorship information and early bird registration, please visit

Media Registration
Media registration is free of charge for all valid press card holders or via provision of formal journalist credentials. Register early by contacting to begin receiving advance meeting materials, media alerts, and access to meeting presenters.

About Alliance for Cancer Gene Therapy
For nearly 20 years, Alliance for Cancer Gene Therapy (ACGT) has funded research that is bringing innovative treatment options to people living with deadly cancers — treatments that save lives and offer new hope to all cancer patients. Founded by Barbara and Edward Netter after their daughter-in-law’s death from breast cancer, ACGT funds researchers who are pioneering the potential of cancer cell and gene therapy — talented visionaries whose scientific advancements are driving the development of groundbreaking treatments for ovarian, prostate, sarcoma, glioblastoma, melanoma and pancreatic cancers. One hundred percent of all public funds raised by ACGT directly support program and research, thanks to separate funding to support administrative expenses.